Compare Stocks: RCUS, MDGL, BMRN, and IBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$55.20 -1.8%	$63.83	$49.26 ▼ $70.98	$10.88B	0.22	2.14 million shs	2.08 million shs
IBRX ImmunityBio	$9.75 +0.6%	$8.20	$1.95 ▼ $12.43	$10.27B	0.02	14.06 million shs	11.75 million shs
MDGL Madrigal Pharmaceuticals	$487.72 -1.8%	$520.00	$393.61 ▼ $615.00	$11.47B	-1.04	245,748 shs	256,245 shs
RCUS Arcus Biosciences	$24.53 +1.0%	$27.66	$14.18 ▼ $31.74	$3.09B	0.94	1.78 million shs	1.60 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-1.81%	-8.06%	-17.03%	-7.95%	+0.91%
IBRX ImmunityBio	+0.62%	+3.28%	+20.67%	+9.92%	+290.00%
MDGL Madrigal Pharmaceuticals	-1.76%	-3.22%	-9.86%	-12.91%	+11.79%
RCUS Arcus Biosciences	+1.00%	-5.26%	-17.31%	-18.31%	+75.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$55.20 -1.8%	$63.83	$49.26 ▼ $70.98	$10.88B	0.22	2.14 million shs	2.08 million shs
IBRX ImmunityBio	$9.75 +0.6%	$8.20	$1.95 ▼ $12.43	$10.27B	0.02	14.06 million shs	11.75 million shs
MDGL Madrigal Pharmaceuticals	$487.72 -1.8%	$520.00	$393.61 ▼ $615.00	$11.47B	-1.04	245,748 shs	256,245 shs
RCUS Arcus Biosciences	$24.53 +1.0%	$27.66	$14.18 ▼ $31.74	$3.09B	0.94	1.78 million shs	1.60 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-1.81%	-8.06%	-17.03%	-7.95%	+0.91%
IBRX ImmunityBio	+0.62%	+3.28%	+20.67%	+9.92%	+290.00%
MDGL Madrigal Pharmaceuticals	-1.76%	-3.22%	-9.86%	-12.91%	+11.79%
RCUS Arcus Biosciences	+1.00%	-5.26%	-17.31%	-18.31%	+75.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.67	Moderate Buy	$89.17	61.55% Upside
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	45.64% Upside
MDGL Madrigal Pharmaceuticals	2.78	Moderate Buy	$710.20	45.62% Upside
RCUS Arcus Biosciences	2.64	Moderate Buy	$38.30	56.12% Upside

Current Analyst Ratings Breakdown

Latest RCUS, MDGL, BMRN, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$43.00
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$704.00
9/24/2026	MDGL Madrigal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$704.00
9/23/2026	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Buy	$725.00
9/23/2026	BMRN BioMarin Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/23/2026	MDGL Madrigal Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$725.00
9/18/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/16/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/16/2026	RCUS Arcus Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/11/2026	RCUS Arcus Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.32	$2.80 per share	19.70	$31.68 per share	1.74
IBRX ImmunityBio	$113.29M	91.21	N/A	N/A	($0.51) per share	-19.12
MDGL Madrigal Pharmaceuticals	$958.40M	11.76	N/A	N/A	$26.54 per share	18.38
RCUS Arcus Biosciences	$247M	12.65	N/A	N/A	$5.84 per share	4.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	149.19	10.18	0.40	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
MDGL Madrigal Pharmaceuticals	-$288.28M	-$12.89	N/A	87.88	N/A	-25.32%	-56.65%	-25.53%	11/3/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest RCUS, MDGL, BMRN, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	IBRX ImmunityBio	-$0.07	N/A	N/A	N/A	$59.23 million	N/A
11/3/2026	Q3 2026	MDGL Madrigal Pharmaceuticals	-$0.8395	N/A	N/A	N/A	$404.67 million	N/A
10/27/2026	Q3 2026	RCUS Arcus Biosciences	-$0.8769	N/A	N/A	N/A	$11.14 million	N/A
10/26/2026	Q3 2026	BMRN BioMarin Pharmaceutical	$1.33	N/A	N/A	N/A	$1.02 billion	N/A
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/30/2026	Q2 2026	MDGL Madrigal Pharmaceuticals	-$2.68	-$1.99	+$0.69	-$1.99	$352.13 million	$364.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
IBRX ImmunityBio	N/A	5.72	5.70
MDGL Madrigal Pharmaceuticals	0.65	3.20	2.94
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
IBRX ImmunityBio	8.58%
MDGL Madrigal Pharmaceuticals	98.50%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
IBRX ImmunityBio	66.10%
MDGL Madrigal Pharmaceuticals	17.60%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
MDGL Madrigal Pharmaceuticals	915	23.10 million	19.04 million	Optionable
RCUS Arcus Biosciences	601	127.33 million	117.66 million	Optionable

RCUS, MDGL, BMRN, and IBRX Headlines

Recent News About These Companies

Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?

October 7 at 3:25 PM | finance.yahoo.com

Arcus Biosciences stock fell 3.13 percent on October 2

October 6 at 1:41 PM | ad-hoc-news.deA

Arcus Biosciences stock gains 1.49 percent ahead of data event

October 6 at 1:41 PM | ad-hoc-news.deA

Wall Street Zen upgrades Arcus Biosciences stock to Hold

October 5 at 8:41 AM | ad-hoc-news.deA

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

October 4, 2026 | finance.yahoo.com

Arcus Biosciences (NYSE:RCUS) Raised to "Hold" at Wall Street Zen

October 3, 2026 | americanbankingnews.com

Arcus Biosciences (NYSE:RCUS) Stock Moved Up to Hold by Wall Street Zen

October 3, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Earns Outperform Rating from Wedbush

September 30, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants - September 24, 2026

September 25, 2026 | biospace.comB

Arcus Biosciences stock trades 16.8 percent below yearly high

September 24, 2026 | ad-hoc-news.deA

835,504 Shares in Arcus Biosciences, Inc. $RCUS Bought by Bank of America Corp DE

September 24, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading Up 3.2% - Should You Buy?

September 23, 2026 | marketbeat.com

Arcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of Therapy

September 22, 2026 | marketscreener.comM

Arcus Biosciences (RCUS) Reiterated at Overweight by Cantor Fitzgerald

September 22, 2026 | streetinsider.com

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

September 22, 2026 | finance.yahoo.com

Arcus Biosciences stock holds steady as investors eye latest clinical and earnings signals

September 21, 2026 | ad-hoc-news.deA

Squarepoint Ops LLC Decreases Stake in Arcus Biosciences, Inc. $RCUS

September 21, 2026 | marketbeat.com

TD Cowen Initiates Arcus Biosciences at Buy

September 16, 2026 | marketscreener.comM

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Analysts

September 16, 2026 | marketbeat.com

Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Shares Down 5.6% - Here's What Happened

September 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, MDGL, BMRN, and IBRX Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$55.20 -1.02 (-1.81%)

Closing price 10/7/2026 04:00 PM Eastern

Extended Trading

$55.28 +0.08 (+0.14%)

As of 07:00 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

ImmunityBio NASDAQ:IBRX

$9.75 +0.06 (+0.62%)

Closing price 10/7/2026 04:00 PM Eastern

Extended Trading

$9.70 -0.04 (-0.46%)

As of 07:21 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$487.72 -8.73 (-1.76%)

Closing price 10/7/2026 04:00 PM Eastern

Extended Trading

$508.87 +21.15 (+4.34%)

As of 07:10 AM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$24.53 +0.25 (+1.04%)

Closing price 10/7/2026 03:58 PM Eastern

Extended Trading

$24.53 0.00 (-0.01%)

As of 10/7/2026 07:30 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, MDGL, BMRN, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, MDGL, BMRN, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, MDGL, BMRN, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, MDGL, BMRN, and IBRX Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, MDGL, BMRN, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, MDGL, BMRN, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, MDGL, BMRN, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, MDGL, BMRN, and IBRX Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools